NAFDAC Alerts Public On Unregistered B-GAG Syrup

 

The National Agency for Food and Drug Administration and Control, NAFDAC has issued a warning to Nigerians against buying an unregistered drug called B-GAG mist pot CIT syrup.

 

The alert is contained in a public notice No. 023/2024, issued by the agency’s Director-General, Prof. Mojisola Adeyeye, in Abuja on Sunday.

 

The unregistered product is alleged to have been sold by a company named Babban Gida Agalawa General Enterprises.

 

The statement said the product, being presented in a pet bottle, was discovered during a surveillance operation carried out by the NAFDAC Post Marketing Surveillance Directorate Officers in Maiduguri, Borno, and Keffi, Nasarawa States.

 

It said that the product was found to be without a NAFDAC registration number and a misleading label.

 

NAFDAC in the statement said illegal marketing of medicines or counterfeit medicines posed a risk to public health.

 

Adeyeye noted that without compliance with regulatory provisions the safety, quality, and efficacy of such products were not guaranteed.

 

The agency gave the batch number of the fake product as 0070, the manufacturing date as 01/02/2024, as well as the expiring date as 01/02/2027.

 

Adeyeye also gave the address of the manufacturer as No. 883/884 Western Bypass Ring Road, Kumbosto Local Government, Kano State.

 

Adeyeye further said that NAFDAC Zonal Directors and State Coordinators had been directed to carry out surveillance to mop up the illegal products within the zones and states.

 

She advised consumers and caregivers to avoid the use of the product, adding that all medical products must be obtained from authorized and licensed suppliers.

 

Adeyeye said that products’ authenticity and physical condition should be carefully checked before purchase or use.

 

She also advised healthcare professionals and consumers to report any suspicion of either the sale of substandard and falsified medicines or medical devices to the nearest NAFDAC office.

 

She encouraged healthcare professionals and patients to report adverse events or side effects related to the use of medicinal products through NAFDAC E-reporting platforms.